companies

Curium is one of the largest nuclear-medicine companies, developing 177Lu-PSMA-I&T (ECLIPSE) as a competitor to Pluvicto.

GE HealthCare, of Chicago, makes PET/CT, MRI and CT scanners (Omni Legend, SIGNA, Revolution) and PET tracers through its Pharmaceutical Diagnostics business, including Cerianna, the fluoroestradiol F-18 agent that images oestrogen receptors in breast cancer. Whether receptor-imaging tracers change treatment decisions often enough to be reimbursed is its tracer business's open question.

The company that made radioligand therapy a business, with Pluvicto and Lutathera, and the maker of Kisqali and Gleevec.

Lantheus makes Pylarify, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026.

AstraZeneca is the most ADC-committed large pharma, co-owner of Enhertu and Datroway, with deep targeted-therapy and radiopharma bets.

Telix is the Australian theranostics company behind Illuccix and Gozellix PSMA imaging and a broad therapeutic pipeline.

Merck & Co. (MSD) makes Keytruda, the world's best-selling cancer drug, and is now building the next act around TROP2 ADCs and personalised vaccines.

The CERN spin-out that Novartis bought in 2018 for Lutathera, which now makes Pluvicto and the Locametz and Netspot imaging kits.

Bayer owns Xofigo, the only approved alpha emitter, and is developing next-generation actinium PSMA agents.

Eli Lilly makes Verzenio and Retevmo, as well as the oral SERD imlunestrant and the BTK inhibitor pirtobrutinib.

Bought Seagen for $43B to become an ADC leader; also makes Ibrance, Lorbrena, Braftovi, and the first PROTAC.

RadioMedix is developing AlphaMedix (212Pb-DOTAMTATE) with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation.

Blue Earth Diagnostics makes Posluma (18F-rhPSMA-7.3) and Axumin (fluciclovine) PET agents for prostate cancer.

Alpha-emitter company acquired by AstraZeneca ($2.4B, 2024); FPI-2265 (225Ac-PSMA-I&T) in phase 3.

Johnson & Johnson leads in multiple myeloma (Darzalex, Carvykti, Tecvayli, Talvey) and in bispecific antibodies for lung cancer (Rybrevant).

Lead-212 alpha-therapy company whose SSTR2 agent [212Pb]VMT-α-NET reported a 43% response rate in neuroendocrine tumours and is heading for phase 3.

ABX is a German maker of the precursors and kits behind PET imaging tracers, including PSMA agents for prostate cancer, and sponsors the trials that register them.

Acrotech Biopharma, part of Aurobindo, owns the former Spectrum Pharmaceuticals haematology portfolio: the radioimmunotherapy Zevalin, pralatrexate (Folotyn), belinostat (Beleodaq) and vincristine liposome (Marqibo).

Actinium Pharmaceuticals attaches the alpha-emitting isotope actinium-225 to antibodies to treat acute myeloid leukaemia and, more recently, solid tumours such as prostate and lung cancer. It is a small listed company whose lead programme is approaching new clinical milestones.

Medical device giant whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer.

Pioneer of checkpoint inhibitors (Opdivo, Yervoy), now betting on the first successful bispecific ADC and alpha radiopharmaceuticals.

Nuclear pharmacy network (>130 sites) that compounds and delivers SPECT and PET doses, and a distributor of oncology drugs to community practices.

China's state-backed isotope and nuclear medicine group: it makes the radioactive material and the medicines that use it.

Clarity Pharmaceuticals, a Sydney radiopharmaceutical company, pairs copper isotopes with SAR-bisPSMA, a molecule that binds PSMA on prostate cancer cells: copper-64 for PET imaging, in the phase 3 AMPLIFY and CLARIFY trials, and copper-67 for therapy in the SECuRE trial. The copper-67 therapy is still at the dose-finding stage.

The Australian company behind Technegas, the inhaled ventilation agent, which spent thirty years as a product the United States could not buy and is now being installed across American hospitals.

FutureChem is a South Korea-based radiopharmaceutical company running 2 late-stage cancer trials of [F-18]Florastamin in prostate cancer.

ITM is the largest non-carrier-added lutetium-177 supplier and the developer of ITM-11 (177Lu-edotreotide).

Jubilant Radiopharma is a radiopharmacy network and the manufacturer of I-131 MIBG (AdreView), Ruby-Fill, and PET tracers.

Navidea developed technetium-99m tilmanocept (Lymphoseek), the radiotracer approved in 2013 for mapping sentinel lymph nodes in breast cancer, melanoma and head and neck cancer.

Orano Med is the leading lead-212 producer and the developer of 212Pb-DOTAMTATE (AlphaMedix).

PETNET Solutions is the largest network of PET radiopharmacies in the US, producing FDG and PSMA tracers daily.

POINT Biopharma developed radioactive medicines that home in on prostate cancer and neuroendocrine tumours, and built a large manufacturing campus in Indianapolis. Eli Lilly bought the company at the end of 2023.

RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3.

Sirtex makes SIR-Spheres, yttrium-90 resin microspheres used for radioembolisation of liver tumours.

SOFIE Biosciences is a US radiopharmacy network running two phase 3 trials of the FAP PET tracer [18F]FAPI-74 in pancreatic and gastro-oesophageal cancer.

Abdera Therapeutics engineered antibodies that carry a radioactive isotope to cancer cells, tuning how long they circulate so more radiation reaches the tumour and less reaches healthy tissue. Its first medicine targets a protein on small cell lung cancer.

An Australian biotech building its own supply of the rare radioactive metal lead-212 so it can make alpha-particle cancer therapies, starting with one for prostate cancer.

Miniprotein alpha-radiopharmaceutical company; the first biotech IPO of 2026 (~$365M) funds Ac-225 programmes against Nectin-4 and B7-H3.

An Israeli company that places tiny radioactive seeds directly inside a solid tumour; the seeds release a burst of highly damaging particles that mostly stay within a few millimetres of the tumour, sparing surrounding healthy tissue.

Alpha-9 Oncology designs bespoke molecules that deliver radioactive isotopes to cancer cells, with early human trials under way in melanoma and in breast and other solid tumours.

ANSTO runs the OPAL research reactor near Sydney and a molybdenum-99 plant that supplies Australia's nuclear medicine and exports, and produces lutetium-177 for radioligand therapy.

Ariceum Therapeutics is a Berlin company developing a treatment that carries the alpha-emitting isotope actinium-225 to small cell lung cancer and Merkel cell skin cancer. Its first human trial began in late 2025.

ARTBIO makes cancer treatments that deliver short-range alpha radiation from lead-212 directly to tumour cells, starting with prostate cancer. Its first medicine is in early human trials, currently paused by the company while it reviews data.

Atomic Alchemy set out to build small reactors dedicated to making the radioactive isotopes used in cancer scans and treatments, so hospitals no longer depend on a handful of ageing government reactors. It was bought by the nuclear company Oklo.

An Italian company that makes the dyes and tracers doctors use to see inside the body on X-ray, CT, MRI, ultrasound and PET/SPECT scans, and, through a subsidiary, some of the radioactive scans used to find prostate cancer.

A Canadian company, owned by the US nuclear firm BWXT, that is building a made-in-Canada supply of the technetium generators hospitals use for the vast majority of nuclear medicine scans, plus other isotopes and radiotherapy hardware.

Canon Medical is the Japanese imaging vendor (formerly Toshiba Medical) with CT, MRI, ultrasound, and the Cartesion Prime PET/CT.

A Korean company developing a lutetium-177 prostate cancer therapy of its own, now filed for conditional approval in Korea.

Cellectar is a New Jersey radiopharmaceutical company whose iodine-131 phospholipid drug conjugate iopofosine targets the lipid rafts of cancer cells, with a pivotal trial (CLOVER-WaM) in relapsed Waldenström macroglobulinaemia.

Comecer, of Castel Bolognese, Italy, and part of ATS Corporation, makes hot cells, isolators and dose calibrators, the shielded enclosures and automation that radiopharmacies need to handle radioactive drugs aseptically. Therapeutic radioligands need more shielding than diagnostic tracers, and whether hospitals build enough of it is the open question.

Convergent Therapeutics attaches an alpha-emitting isotope to an antibody that homes in on prostate cancer cells, for men whose disease has progressed after standard radioligand treatment. Its lead medicine has reported mid-stage trial results.

Korea's biggest maker of diagnostic PET tracers, now building the country's first plant for radioactive cancer therapies.

German isotope and radiopharmaceutical services company supplying Lu-177, Ga-68 generators, Ac-225 development, and contract manufacturing.

Evergreen Theragnostics manufactures radioactive cancer medicines for other companies and develops its own imaging agent for neuroendocrine tumours and a treatment for small cell lung cancer. Lantheus agreed to buy it in 2025.

A radiopharmaceutical drug developer with sites in Europe and China that designs its own targeting molecules and pairs them with radioactive actinium or lutetium; its biggest programme, for a receptor found on several solid tumour types, has been licensed to a Korean partner in a deal worth up to $571.5 million.

Hamamatsu is the photonics company behind the NanoZoomer slide scanners and the photodetectors inside most PET scanners.

The Chinese state group's radiopharmaceutical arm, and the first company to make germanium-68 generators' feedstock at scale in China.

IBA (Ion Beam Applications), of Louvain-la-Neuve, Belgium, is the largest supplier of proton therapy equipment: its Proteus One and Proteus Plus systems equip proton centres worldwide, and it also builds cyclotrons for PET isotope production. Proton therapy's capital cost is the problem its compact systems try to answer.

A Michigan company that builds compact superconducting particle accelerators and uses them to make radioactive materials for both diagnostic scans and cancer therapies, including two rare isotopes, actinium-225 and astatine-211.

IRE in Belgium is one of the world's few molybdenum-99 processors, taking irradiated targets from European research reactors, and its IRE ELiT arm makes the Galli Eo gallium-68 generator.

Isotopia is an Israeli producer of non-carrier-added lutetium-177 and PET tracers that supplies several radioligand developers.

A company that makes Neuraceq, an injectable radioactive tracer that lights up Alzheimer's plaques on a PET brain scan, and is now owned by Lantheus.

Mariana Oncology designs small protein fragments that carry a radioactive isotope to tumours, starting with small cell lung cancer. Novartis bought the company in 2024 for 1 billion dollars up front.

Mediso is a Hungarian nuclear medicine company making AnyScan SPECT/CT and PET/CT cameras for hospitals and nanoScan PET/MRI and SPECT/CT scanners for preclinical research.

Contouring, image fusion, and dosimetry software (MIM Maestro, SurePlan) for radiotherapy and radioligand therapy, acquired by GE HealthCare in 2024.

A Pennsylvania biotech that adds a chemical 'handle' to existing radioactive cancer drugs so the drug binds briefly to albumin, the body's most abundant blood protein, letting it linger in the tumour for days on a fraction of the usual radiation dose.

Monopar is a Chicago-area biotech that took the mucositis drug validive into a phase 3 trial in head and neck cancer, which failed in 2023, and now develops radiopharmaceuticals against the uPAR protein.

Japan's largest maker of radioactive tracers for scans, now wholly owned by GE HealthCare.

A Michigan company that produces medical radioactive materials, including some used for cancer treatment, using a superconducting particle accelerator instead of a nuclear reactor.

Nordion supplies most of the world's cobalt-60, which sterilises single-use bioprocess bags and medical devices and powers Gamma Knife units, and was the largest molybdenum-99 processor until Canada's NRU reactor stopped.

NorthStar is a non-reactor producer of Mo-99 in the US and an emerging supplier of non-carrier-added Lu-177 and Ac-225 made with electron accelerators.

NTP, part of South Africa's state nuclear corporation, processes molybdenum-99 and other isotopes from the SAFARI-1 reactor and was the first major producer to switch to low-enriched uranium targets.

Nucleus RadioPharma does not make its own cancer drugs; it manufactures and ships radioactive cancer medicines for other companies, which is hard because the drugs decay within days. It is expanding its plants in Minnesota and Pennsylvania.

A Swiss biotech using two forms of radioactive copper, one for scanning and one for treatment, joined to the same targeting molecule so the same drug design can both find and then destroy a tumour.

Nusano is a Utah company building an isotope production plant around its own ion beam technology, aiming at actinium-225 and other therapeutic isotopes that are in short supply.

A German medical device company that makes a skin-patch radiotherapy for early skin cancer: a paste containing a radioactive isotope, rhenium-188, is applied over the tumour for under three hours instead of surgery.

The Japanese radiopharmaceutical business that PeptiDream bought from FUJIFILM: it sells most of Japan's radioactive diagnostics and the therapies that go with them.

Precirix, of Brussels, develops radiopharmaceuticals built on small single-domain antibody fragments that carry a radioactive isotope to HER2-positive cancers. Its lead, CAM-H2, is in a phase 1/2 trial in HER2-positive breast, gastric and gastro-oesophageal cancer, including patients with brain metastases, with an imaging dose given first to confirm HER2 in the lesions.

A Dutch company, owned by Terumo, that makes tiny radioactive beads containing holmium-166 which are injected into the liver's blood vessels to irradiate liver tumours from the inside, plus the imaging tools used to plan and check that treatment.

Radionetics Oncology makes small-molecule drugs that carry a radioactive isotope to receptors on the surface of cancer cells that have rarely been targeted before. Eli Lilly paid 140 million dollars in 2024 for the right to buy the company for 1 billion dollars.

Radiopharm Theranostics is an Australia-based radiopharmaceutical company that leads 3 cancer trials in Nuclide, testing the radiopharmaceuticals 161Tb-RAD402, 177Lu-BetaBart and the PET tracer RAD101 in prostate cancer, colorectal cancer, non-small-cell lung cancer and ovarian cancer.

Ratio Therapeutics, of Boston, designs small molecules that carry a radioactive isotope to fibroblast activation protein, a protein on the supporting tissue of sarcomas and other solid tumours, so radiation is delivered from inside the body. Its lead, an actinium-225 radioligand, is in the ATLAS phase 1/2 trial in advanced sarcomas.

SHINE Technologies is a fusion-based isotope company that produces non-carrier-added Lu-177 (Ilumira) and is building the Chrysalis Mo-99 plant.

Siemens Healthineers makes the Biograph Vision Quadra total-body PET and photon-counting CT, and owns Varian.

Sinotau Pharmaceutical is a China-based radiopharmaceutical company running 2 late-stage cancer trials of Octreotide LAR in neuroendocrine tumours.

Spectrum Pharmaceuticals was a US cancer company that sold its haematology portfolio to Acrotech in 2019, won approval for the long-acting G-CSF eflapegrastim (Rolvedon) in 2022, and was acquired by Assertio in 2023.

Bill Gates-backed producer of actinium-225 from thorium-229, building a Philadelphia facility to raise supply 20-fold.

Belgian maker of radiopharmaceutical synthesis modules (AllinOne, miniAiO) and dose dispensers used in PET and therapy radiopharmacies.

Chinese imaging company that built uEXPLORER, the first total-body PET scanner.

MSK spin-out that commercialises naxitamab, the humanised anti-GD2 antibody for relapsed neuroblastoma, and develops pretargeted radioimmunotherapy.